Diabetes regulated anti-inflammatory lncRNA is overexpressed in triple-negative breast cancer and predicts chemoresistance and tumor recurrence-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Diabetes regulated anti-inflammatory lncRNA is overexpressed in triple-negative breast cancer and predicts chemoresistance and tumor recurrence

Published:2022-05-02 Issue:5 Volume:13 Page:12718-12725
ISSN:2165-5979
Container-title:Bioengineered
language:en
Short-container-title:Bioengineered

Author:

Wang Peng¹,Peng Wei²,Peng Jian³^ORCID

Affiliation:

1. Department of Physical Examination Center, Peking University Third Hospital, Beijing, China

2. Department of Xiangya Medical Academic Promotion Center, Xiangya Hospital Central South University, Changsha City, China

3. Department of General Surgery, Xiangya Hospital Central South University, Changsha City, China

Funder

reported

Publisher

Informa UK Limited

Subject

Applied Microbiology and Biotechnology,General Medicine,Bioengineering,Biotechnology

Link

https://www.tandfonline.com/doi/pdf/10.1080/21655979.2022.2068821

Reference21 articles.

1. Breast Cancer Treatment

2. Breast cancer statistics, 2019

3. Consumer credit as a novel marker for economic burden and health after cancer in a diverse population of breast cancer survivors in the USA

4. Early Diagnosis of Breast Cancer

5. Triple-negative breast cancer molecular subtyping and treatment progress

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA;International Journal of Molecular Sciences;2023-11-02

2. Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy;Diagnostics;2023-07-17

3. Towards dual function of autophagy in breast cancer: A potent regulator of tumor progression and therapy response;Biomedicine & Pharmacotherapy;2023-05

4. The role of lncRNAs in regulation of DKD and diabetes-related cancer;Frontiers in Oncology;2022-10-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3